Latest studies
- RecruitingPHASE2, PHASE3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
This study looks at a new medicine called ponsegromab for advanced pancreatic cancer that has spread, especially when patients have lost a lot of weight and feel very tired. It aims to see if adding ponsegromab to standard chemotherapy helps more than chemotherapy alone.
CachexiaMetastatic Pancreatic Ductal AdenocarcinomaSlovakia - RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaSlovakia - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)Slovakia - Completed
Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with mild, moderate or severe skin conditions
Acne is a common skin condition that affects confidence and well-being. This study tests whether a daily skincare routine using Eucerin products helps clear mild to severe spots. Researchers want to see how well these creams work over a year in people aged 12 to 50 across the UK and worldwide.
Subjects with acne-prone skin aged 12-50 years with Investigator's Global Assessment (IGA) grades 2-4, evaluating treatment of mild to severe acne vulgaris.Slovakia - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseSlovakia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
This study is testing a new tablet called CRD-4730 for adults with heart failure. Researchers want to see if the medicine can help the heart pump blood better, ease everyday symptoms, and improve quality of life. Participants will take either the study drug or a dummy pill for 24 weeks.
heart failureSlovakia - AuthorisedTherapeutic exploratory (Phase II)
A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)
This clinical study tests an experimental gel called EscharEx for treating venous leg ulcers. Researchers want to find out if it safely removes dead tissue from the wound and speeds up healing compared to a dummy gel or usual non-surgical care. It is open to adults aged 18 and over.
Venous Leg Ulcer (VLU)Slovakia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
This study tests a medicine called Vyvgart in adults with Sjögren's disease who have nerve damage in their hands, legs, or feet. Researchers want to see if regular injections under the skin can ease nerve symptoms, reduce fatigue, and be used safely compared with a dummy treatment.
Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)Slovakia - AuthorisedTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
This study looks at the long-term safety of a new medicine called KT-621 for adults with moderate to severe eosinophilic asthma. It is an extension study for people who already took part in an earlier KT-621 trial, checking how well the body tolerates the treatment over 52 weeks.
Uncontrolled Moderate to Severe Eosinophilic AsthmaSlovakia - AuthorisedTherapeutic exploratory (Phase II)
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)
This study tests a new daily tablet called AC01 for people with long-term heart failure. Researchers want to see if this medicine can help the heart pump blood more effectively. Participants take either the real medicine or a dummy tablet for 12 weeks while doctors monitor their heart health.
chronic advanced heart failure with reduced ejection fraction (HFrEF)Slovakia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight
This study tests a new medicine called AZD6234 for adults living with type 2 diabetes who are also overweight or obese. Researchers want to see if the medicine helps people safely lose weight, improve their blood sugar levels, and lower their blood pressure over 68 weeks compared to a dummy drug.
Obesity or overweightDiabetes Mellitus, Type 2Slovakia - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study)
This study tests a new injection called plozasiran in adults with high levels of blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fats over one year compared to a dummy jab (placebo). This could help reduce risks to the heart and pancreas.
HypertriglyceridemiaSlovakia - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)
This Phase 3 clinical study tests a new injection called plozasiran for adults with very high blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fat levels over 12 months compared to a dummy jab, reducing the risk of painful pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Slovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
This study is testing a new tablet, called BLU-5937, for adults with a chronic cough that will not go away despite usual treatments. Researchers want to see if taking the tablet for 24 weeks safely reduces how often people cough during the day and night.
Refractory Chronic Cough, Including Unexplained Chronic CoughSlovakia - RecruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
This clinical trial is testing a new injection called efgartigimod for adults with inflammatory muscle disease (myositis). Researchers want to see if the medicine can safely reduce muscle inflammation, improve strength, and help people lower their daily steroid dose compared to a dummy treatment over 52 weeks.
Active Idiopathic Inflammatory Myopathy (IIM)Slovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema
This clinical trial is testing a new daily tablet called deucrictibant for adults with hereditary angioedema (HAE). Researchers want to find out if taking this tablet can safely prevent painful swelling attacks. Participants will take either the study tablet or an inactive dummy pill for 24 weeks.
Hereditary AngioedemaSlovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseaseSlovakia - RecruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
This study tests a new tablet version of mesalazine for people with mild to moderate ulcerative colitis. Researchers want to see if it is just as safe and effective as an established treatment at calming gut inflammation and helping symptoms settle down after eight weeks of daily treatment.
Ulcerative colitisSlovakia - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)
This study tests a new injection called plozasiran for adults with very high blood fat levels, known as severe hypertriglyceridemia. Researchers want to see if the medicine can safely lower blood fats over one year compared to a dummy jab, reducing the risk of serious problems like pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Slovakia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomised, Double-Blind, Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE).
This study tests a new once-daily inhaled medicine called AZD8630 for adults with asthma. Researchers want to see if different doses can help prevent asthma flare-ups and improve breathing in people whose symptoms are not fully controlled by their usual daily inhalers.
Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.Slovakia - RecruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)
This study tests a new medicine called ianalumab for adults with active Sjögren's syndrome. Researchers want to see if regular injections can calm the immune system, ease severe tiredness, and improve dry eyes and mouth compared to a dummy jab (placebo) over 48 weeks of treatment.
Sjögren’s SyndromeSlovakia - RecruitingTherapeutic confirmatory (Phase III)
A multicenter, open-label, single-arm study to evaluate long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy
This study looks at the long-term safety of an epilepsy medicine called brivaracetam. It is for adults living with childhood or juvenile absence epilepsy, a condition causing brief daydream-like pauses. Researchers want to see how well patients tolerate the medicine and track any side effects over time.
Childhood Absence Epilepsy, Juvenile Absence EpilepsySlovakia - AuthorisedPhase III and phase IV (Integrated)
A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)
This study is looking at a medicine called saroglitazar magnesium for people living with primary biliary cholangitis (PBC). Researchers want to see if this daily tablet can protect the liver from long-term damage, reduce extreme tiredness, and lower the risk of serious complications or needing a liver transplant.
Primary Biliary Cholangitis (PBC)Slovakia - AuthorisedTherapeutic exploratory (Phase II)
An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a Novartis sponsored alpelisib (BYL719) study and are judged by the Investigator to benefit from continued treatment with alpelisib.
This study is an extension study for adults who have already taken the medicine alpelisib in a previous clinical trial for breast cancer or a rare overgrowth condition called PROS. It allows patients to continue their treatment while doctors monitor its long-term safety and how well it keeps working.
• PROS (PIK3CA‑Related Overgrowth Spectrum) and,• Breast Neoplasms [UMLS CUI term]Slovakia - AuthorisedPhase II and Phase III (Integrated)
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
This clinical trial is testing a medicine called pegcetacoplan for people with focal segmental glomerulosclerosis (FSGS), a rare kidney condition. Researchers want to see if the treatment safely reduces the amount of protein leaking into the urine and helps protect kidney function over time.
Focal segmental glomerulosclerosis (FSGS)Slovakia - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
This clinical trial is testing new blood-thinning medicines for adults with peripheral artery disease who recently had a procedure to restore blood flow in their legs. Researchers want to find out if these medicines can prevent serious blood clots, heart attacks, and amputations without causing major bleeding problems.
Peripheral Artery DiseaseSlovakia - RecruitingTherapeutic confirmatory (Phase III)
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease
This study tests a new injection called pelacarsen for adults with heart disease. Researchers want to see if lowering a specific blood fat, called lipoprotein(a), helps prevent serious heart problems like heart attacks and strokes. Half the participants will receive the medicine and half will receive a dummy injection.
Cardiovascular DiseaseSlovakia - RecruitingTherapeutic confirmatory (Phase III)
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
The ZEUS study is looking at whether a new medicine called ziltivekimab can protect people with heart and kidney problems. Researchers want to see if lowering body swelling and inflammation can reduce the chances of serious health events like heart attacks, strokes, or worsening kidney disease.
Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammationSlovakia - AuthorisedTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)
This clinical trial looks at a new injection form of letrozole, a common hormone therapy for advanced breast cancer. Researchers want to see if this long-acting injection works just as well as daily tablets at slowing cancer growth, while also comparing side effects like joint and muscle aches.
HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancerSlovakia - RecruitingPhase II and Phase III (Integrated)
A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
This study is looking at a medicine called brivaracetam to see how well it works and if it's safe for children and young people (ages 2 to 25) with certain types of epilepsy (Childhood Absence Epilepsy or Juvenile Absence Epilepsy). It's comparing the medicine to a dummy pill (placebo) to see if it reduces seizures.
Childhood Absence EpilepsyJuvenile Absence EpilepsySlovakia - RecruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisSlovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This study is looking at a medicine called ozanimod for people with Crohn's disease that is moderate to severe. It wants to see how well the medicine helps reduce their symptoms and improve their gut health over a long period. Researchers will also check how it affects COVID-19 antibody levels.
Moderately to Severely Active Crohn's DiseaseSlovakia - RecruitingTherapeutic confirmatory (Phase III)
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
This study is looking at the long-term safety of a medicine called cenobamate for adults who have a certain type of seizure called primary generalized tonic-clonic seizures. It's an extension of a previous study, continuing to check how safe the medicine is over time.
Primary Generalized Tonic-Clonic SeizuresSlovakia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Slovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration
This study is testing a new version of an eye medicine, ranibizumab (like Lucentis), for wet age-related macular degeneration. Researchers want to see if the new version works as well and is as safe as the original to help people see better.
wet macula degenerationSlovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
This study is looking into a new treatment, RBS-001, for a specific eye condition called wet age-related macular degeneration (wet AMD). It compares RBS-001 with an existing treatment, Eylea, to see if it works as well or better, and if it's safe for patients.
Neovascular age-related macular degeneration (nAMD)Slovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy
This study looks at a new treatment for people with a certain type of lung cancer that has been removed by surgery. It compares two medicines, Tiragolumab and Atezolizumab, against Atezolizumab alone, to see if the new combination can help prevent the cancer from coming back.
Non-Small Cell Lung CancerSlovakia - RecruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
Relapsing Multiple SclerosisSlovakia - RecruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s disease, Ulcerative colitisSlovakia - RecruitingPhase II and Phase III (Integrated)
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)
This study is looking at a new medicine called spesolimab for a skin condition called Hidradenitis Suppurativa, or HS. It's an extension study, meaning some people might have tried it before. Researchers want to see how safe and effective it is over a longer time.
Hidradenitis Suppurativa (HS)Slovakia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Slovakia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
This study looks at a new medicine called Efavaleukin Alfa for people with moderate to severe ulcerative colitis. It's a long-term study to see how safe and effective the medicine is over a year or two, especially regarding side effects.
Ulcerative Colitis (UC)Slovakia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This study is looking at a new medicine called Danicopan for a type of age-related macular degeneration (AMD) called geographic atrophy (GA). Researchers want to see if the medicine can slow down vision loss and the growth of blind spots.
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)Slovakia - RecruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
This study is testing a new medicine, ISIS 678354, for people with very high levels of a type of fat in their blood called triglycerides. It aims to see if the medicine can lower these levels compared to a dummy medicine.
Severe Hypertriglyceridemia.Slovakia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
This study looks at a new medicine called tildrakizumab (also known as Ilumetri) for people with psoriatic arthritis who haven't responded well to other treatments. It aims to see if tildrakizumab can help reduce joint pain and swelling better than a dummy medicine.
Psoriatic ArthritisSlovakia - RecruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaSlovakia - RecruitingTherapeutic exploratory (Phase II)
C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY
This study is looking at new drug combinations for people with a certain type of advanced melanoma that has not responded to previous treatment. It compares two groups of medicines to see which works better at shrinking the cancer.
Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanomaSlovakia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease
This study looks at how safe and effective a drug called Upadacitinib is over a long time for people with Crohn's disease. It checks if the drug helps people feel better and if they stay better, as well as any side effects.
Crohn's Disease (CD)Slovakia - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
This study is testing a new medicine, cenobamate, for people in the UK and other countries who have a specific type of epilepsy seizure called Primary Generalized Tonic-Clonic seizures. Researchers want to see if it reduces how often these seizures happen and if it's safe to use.
Primary Generalized Tonic-Clonic SeizuresSlovakia - RecruitingTherapeutic confirmatory (Phase III)
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
This study is looking at a new treatment called Newnorm for people with primary immunodeficiency. It's an injection under the skin. We want to see how well it prevents infections and if it's safe. It will also check how the body uses the medicine.
Human Normal ImmunoglobulinSlovakia